Elevating thyroid health: Supporting confident clinical decisions
Friday, August 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Thyroid disorders, including differentiated thyroid cancer, affect millions of patients worldwide and place a growing burden on healthcare systems. As testing volumes increase and clinical pathways evolve, consistent interpretation of results aligned with evidence-based guidelines remains a key challenge for both clinicians and laboratorians.
To address this need, this SelectScience® webinar, presented by Dr. Ossama M. Lashin, Cleveland Clinic, will begin with an educational overview of key updates from the 2025 American Thyroid Association (ATA) guidelines, focusing on how these recommendations inform contemporary thyroid disease evaluation, risk stratification, and long-term monitoring strategies.
The webinar will then explore the clinical utility of thyroglobulin and anti thyroglobulin testing, highlighting their role in disease surveillance for differentiated thyroid cancer. Real world clinical examples will be used to illustrate how guideline anchored testing strategies can support confident clinical decision making and improve diagnostic consistency.
In conclusion, Dr. Lashin will present a clinically oriented, integrated approach to elevating thyroid health, connecting ATA guideline recommendations with practical testing considerations spanning disease assessment, longitudinal monitoring, and outcome focused patient management.
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Instruction level: Intermediate
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
- Endocrinology medicine specialists
- Clinical pathologists and laboratory directors
- Clinical chemists and medical technologists
- Hospital administrators and care coordinators
- Researchers and healthcare policymakers
- Medical science liaisons and medical affairs professionals
- Professionals involved in diagnostic test implementation or differentiated thyroid cancer risk stratification
What will this webinar cover?
Key learning objectives:
- Describe key updates from the 2025 American Thyroid Association guidelines and explain how these recommendations inform current approaches to thyroid disease evaluation, risk stratification, and long-term monitoring.
- Explain the clinical role of thyroglobulin and anti thyroglobulin testing in the management of differentiated thyroid cancer, including appropriate use in disease surveillance and result interpretation.
- Apply guideline aligned testing principles to clinical scenarios to support consistent interpretation of results and informed decision making across disease assessment and longitudinal patient monitoring.